{"id":"NCT02605837","sponsor":"Shire","briefTitle":"A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved","officialTitle":"Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-07","primaryCompletion":"2019-01-24","completion":"2019-02-15","firstPosted":"2015-11-16","resultsPosted":"2020-03-16","lastUpdate":"2025-02-19"},"enrollment":318,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Eosinophilic Esophagitis (EoE)"],"interventions":[{"type":"DRUG","name":"Oral Budesonide Suspension (OBS)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Oral Budesonide Suspension (OBS)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A study in adolescents and adults with eosinophilic esophagitis (EoE) to measure the histologic response and determine if any reduction in dysphagia is achieved.","primaryOutcome":{"measure":"Number of Participants With Histologic Response at the Final Treatment Period Evaluation (Week 16)","timeFrame":"Week 16","effectByArm":[{"arm":"Placebo","deltaMin":1,"sd":null},{"arm":"Oral Budesonide Suspension (OBS)","deltaMin":113,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"11 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":24},"locations":{"siteCount":77,"countries":["United States"]},"refs":{"pmids":["39735351","39631042","37718471","34182150","33887475"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":105},"commonTop":["Nasopharyngitis","Sinusitis","Oesophageal candidiasis","Nausea","ACTH stimulation test abnormal"]}}